"Health Canada approves Novartis’ Fabhalta for PNH with haemolytic anaemia" was originally created and published by ...

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Amid a broader push to beef up cell and gene therapy manufacturing capacity in Europe, Novartis has opened the doors to a €40 ...

Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug ...

Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.

Novartis today announced that it has entered into an agreement to acquire privately-held Anthos Therapeutics, which the Swiss ...

As the first first Novartis viral vector production facility in Europe, it significantly expands Novartis' research and ...

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently in P ...

We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. In this article, we are ...

who was the Division Head of Novartis Pharmaceuticals. He announced his retirement as Chairman of the Board of Directors and was succeeded by Jorg Reinhard in August 2013. Since its establishment ...

The pharma giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to boost its ...

Daniel Ghinn spotlights how this pharma company is facilitating take ... reads a recent tweet from @NovartisCancrUS, Novartis' Twitter channel dedicated to its cancer trials in the US.